147 related articles for article (PubMed ID: 38684824)
1. PRMT9 inhibition sparks immune responses in AML.
Santoro A; Di Micco R
Nat Cancer; 2024 Apr; 5(4):539-541. PubMed ID: 38684824
[No Abstract] [Full Text] [Related]
2. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.
Dong H; He X; Zhang L; Chen W; Lin YC; Liu SB; Wang H; Nguyen LXT; Li M; Zhu Y; Zhao D; Ghoda L; Serody J; Vincent B; Luznik L; Gojo I; Zeidner J; Su R; Chen J; Sharma R; Pirrotte P; Wu X; Hu W; Han W; Shen B; Kuo YH; Jin J; Salhotra A; Wang J; Marcucci G; Luo YL; Li L
Nat Cancer; 2024 Apr; 5(4):601-624. PubMed ID: 38413714
[TBL] [Abstract][Full Text] [Related]
3. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
[TBL] [Abstract][Full Text] [Related]
4. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
Tarighat SS; Santhanam R; Frankhouser D; Radomska HS; Lai H; Anghelina M; Wang H; Huang X; Alinari L; Walker A; Caligiuri MA; Croce CM; Li L; Garzon R; Li C; Baiocchi RA; Marcucci G
Leukemia; 2016 Apr; 30(4):789-99. PubMed ID: 26536822
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Feoli A; Iannelli G; Cipriano A; Milite C; Shen L; Wang Z; Hadjikyriacou A; Lowe TL; Safaeipour C; Viviano M; Sarno G; Morretta E; Monti MC; Yang Y; Clarke SG; Cosconati S; Castellano S; Sbardella G
J Med Chem; 2023 Oct; 66(19):13665-13683. PubMed ID: 37560786
[TBL] [Abstract][Full Text] [Related]
6. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
Radzisheuskaya A; Shliaha PV; Grinev V; Lorenzini E; Kovalchuk S; Shlyueva D; Gorshkov V; Hendrickson RC; Jensen ON; Helin K
Nat Struct Mol Biol; 2019 Nov; 26(11):999-1012. PubMed ID: 31611688
[TBL] [Abstract][Full Text] [Related]
7. Loss-of-function mutation in PRMT9 causes abnormal synapse development by dysregulation of RNA alternative splicing.
Shen L; Ma X; Wang Y; Wang Z; Zhang Y; Pham HQH; Tao X; Cui Y; Wei J; Lin D; Abeywanada T; Hardikar S; Halabelian L; Smith N; Chen T; Barsyte-Lovejoy D; Qiu S; Xing Y; Yang Y
Nat Commun; 2024 Apr; 15(1):2809. PubMed ID: 38561334
[TBL] [Abstract][Full Text] [Related]
8. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
9. Unique Features of Human Protein Arginine Methyltransferase 9 (PRMT9) and Its Substrate RNA Splicing Factor SF3B2.
Hadjikyriacou A; Yang Y; Espejo A; Bedford MT; Clarke SG
J Biol Chem; 2015 Jul; 290(27):16723-43. PubMed ID: 25979344
[TBL] [Abstract][Full Text] [Related]
10. PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145.
Yang Y; Hadjikyriacou A; Xia Z; Gayatri S; Kim D; Zurita-Lopez C; Kelly R; Guo A; Li W; Clarke SG; Bedford MT
Nat Commun; 2015 Mar; 6():6428. PubMed ID: 25737013
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
Fong JY; Pignata L; Goy PA; Kawabata KC; Lee SC; Koh CM; Musiani D; Massignani E; Kotini AG; Penson A; Wun CM; Shen Y; Schwarz M; Low DH; Rialdi A; Ki M; Wollmann H; Mzoughi S; Gay F; Thompson C; Hart T; Barbash O; Luciani GM; Szewczyk MM; Wouters BJ; Delwel R; Papapetrou EP; Barsyte-Lovejoy D; Arrowsmith CH; Minden MD; Jin J; Melnick A; Bonaldi T; Abdel-Wahab O; Guccione E
Cancer Cell; 2019 Aug; 36(2):194-209.e9. PubMed ID: 31408619
[TBL] [Abstract][Full Text] [Related]
12. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
13. MiRNA-543 promotes osteosarcoma cell proliferation and glycolysis by partially suppressing PRMT9 and stabilizing HIF-1α protein.
Zhang H; Guo X; Feng X; Wang T; Hu Z; Que X; Tian Q; Zhu T; Guo G; Huang W; Li X
Oncotarget; 2017 Jan; 8(2):2342-2355. PubMed ID: 27911265
[TBL] [Abstract][Full Text] [Related]
14. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling.
Jiang H; Zhou Z; Jin S; Xu K; Zhang H; Xu J; Sun Q; Wang J; Xu J
Cancer Sci; 2018 May; 109(5):1414-1427. PubMed ID: 29603830
[TBL] [Abstract][Full Text] [Related]
15. FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues.
Cook JR; Lee JH; Yang ZH; Krause CD; Herth N; Hoffmann R; Pestka S
Biochem Biophys Res Commun; 2006 Apr; 342(2):472-81. PubMed ID: 16487488
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.
Mussai F; De Santo C; Abu-Dayyeh I; Booth S; Quek L; McEwen-Smith RM; Qureshi A; Dazzi F; Vyas P; Cerundolo V
Blood; 2013 Aug; 122(5):749-58. PubMed ID: 23733335
[TBL] [Abstract][Full Text] [Related]
17. Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia.
Guo Z; Zhang Z; Yang H; Cao D; Xu X; Zheng X; Chen D; Wang Q; Li Y; Li J; Du Z; Wang X; Chen L; Ding J; Shen J; Geng M; Huang X; Xiong B
J Med Chem; 2019 Jun; 62(11):5414-5433. PubMed ID: 31117515
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic cancer vaccine therapy for acute myeloid leukemia.
Wu M; Wang S; Chen JY; Zhou LJ; Guo ZW; Li YH
Immunotherapy; 2021 Jul; 13(10):863-877. PubMed ID: 33955237
[TBL] [Abstract][Full Text] [Related]
19. Harnessing the immune system in acute myeloid leukaemia.
Austin R; Smyth MJ; Lane SW
Crit Rev Oncol Hematol; 2016 Jul; 103():62-77. PubMed ID: 27247119
[TBL] [Abstract][Full Text] [Related]
20. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
Zeng Z; Maiti A; Herbrich S; Cai T; Cavazos A; Manzella T; Ma H; Hayes K; Matthews J; DiNardo CD; Daver NG; Konopleva MY
Cancer; 2023 Feb; 129(4):531-540. PubMed ID: 36477735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
